[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100647380":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":49,"collaborators":24,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":24,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":24,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":24,"overallStatus":36,"whyStopped":24,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Cairo University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group A","EXPERIMENTAL","Patients will receive 0.5 mg\u002Fkg intravenous ketamine hydrochloride.",[13],"Drug: 0.5 mg\u002Fkg intravenous ketamine",{"label":15,"type":10,"description":16,"interventionNames":17},"Group B","Patients will receive 0.75 mg\u002Fkg intravenous ketamine hydrochloride.",[18],"Drug: 0.75 mg\u002Fkg intravenous ketamine",[20,25],{"type":21,"name":22,"description":11,"armGroupLabels":23,"otherNames":24},"DRUG","0.5 mg\u002Fkg intravenous ketamine",[9],null,{"type":21,"name":26,"description":16,"armGroupLabels":27,"otherNames":24},"0.75 mg\u002Fkg intravenous ketamine",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Hebatullah S Abdelhamid, MD","CONTACT","00201044512277","drhebasalah593@gmail.com",[35],{"facility":5,"status":36,"city":37,"state":24,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Cairo","12613","Egypt","EG",{"type":42,"coordinates":43},"Point",[44,45],31.24967,30.06263,{"lat":45,"lon":44},[48],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Hebatallah Salah Abdelhamid","Lecturer of Anesthesia, Surgical Critical Care and Pain Management Department, Faculty of Medicine, Cairo University, Cairo, Egypt.","100647380","two-intravenous-doses-of-ketamine-in-reducing-the-oculocardiac-reflex-in-adult-patients-undergoing-ophthalmic-surgery-100647380",false,"NCT07708740","Two Intravenous Doses of Ketamine in Reducing the Oculocardiac Reflex in Adult Patients Undergoing Ophthalmic Surgery","Evaluation of Two Intravenous Doses of Ketamine in Reducing the Oculocardiac Reflex in Adult Patients Undergoing Ophthalmic Surgery: A Randomized Controlled Double-Blinded Trial","Inclusion Criteria:\n\n* Age from 18 to 65 years old.\n* Both sexes.\n* American Society of Anesthesiologists (ASA) physical status I, II.\n* Scheduled for elective ophthalmic surgery involving extraocular muscle traction under general anesthesia.\n\nExclusion Criteria:\n\n* Ketamine contraindications (e.g., hypersensitivity, uncontrolled hypertension)\n* History of cardiac arrhythmia or conduction disorder\n* Glaucoma or raised intraocular pressure\n* ASA status greater than II\n* Patient refusal.","ALL","18 Years","65 Years",{"count":64,"type":65},40,"ESTIMATED","INTERVENTIONAL",[68],"NA","This study aims to evaluate whether a lower dose of ketamine (0.5 mg\u002Fkg IV) may be as effective as a higher dose (0.75 mg\u002Fkg IV) in reducing oculocardiac reflex (OCR) incidence in adult patients undergoing ophthalmic surgery.",[71,72,73],"Ketamine","Oculocardiac Reflex","Ophthalmic Surgery","2026-07-11",{"date":76,"type":77},"2026-07-16","ACTUAL",{"date":79,"type":77},"2026-07-01",{"date":81,"type":65},"2027-12-30",{"name":5,"class":6},1]